CARA

Oruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer

Retrieved on: 
Wednesday, April 24, 2024
University, CMO, Safety, NDA, Skin, Leo Pharma, Dermatology, Doctor of Philosophy, Freedom, Engineering, Patient, Doctor of Pharmacy, Secukinumab, Psoriasis, Therapy, Celgene, Biotechnology, Chronic kidney disease, Pharmaceutical industry

WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced the strengthening of its leadership team with the addition of two experienced executives.

Key Points: 
  • Joana Goncalves, MBChB, will serve as Oruka’s Chief Medical Officer, effective April 18, 2024.
  • Dr. Goncalves brings two decades of leadership experience in dermatology clinical development and medical affairs.
  • Oruka also announced that Eugenia Levi, PharmD, will join the company as Vice President of Medical Affairs.
  • Her extensive leadership experience will prove invaluable as we advance our portfolio of potentially best-in-class antibodies and build a high-performing team,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics.

carafem Expands Compassionate, Convenient 24/7 Telehealth Abortion Care to New York

Retrieved on: 
Wednesday, April 24, 2024
Convenience Store, Telemedicine, Virtual Medicine, Vacation, Health Technology, Women, Science, Seniors, Retail, Men, Health, Family, Consumer, Online Retail, Discount, Variety, Teens, Baby, Maternity, Healthcare Reform, Public Policy, Other Policy Issues, LGBTQ+, Travel, Practice Management, Elections, Campaigns, Other Health, General Health, Government, Pharmaceutical, Other Science, FDA, City, Mifepristone, Misoprostol, Language, Privacy, Gender identity, Physician, New Yorker, Pregnancy, Skin, Birth control

carafem , the nation’s most trusted provider of telehealth abortion care, announced today the expansion of its private, personalized abortion services across the state of New York.

Key Points: 
  • carafem , the nation’s most trusted provider of telehealth abortion care, announced today the expansion of its private, personalized abortion services across the state of New York.
  • carafem will provide New Yorkers with a reliable and convenient telehealth option for abortion care, available any time of day or night starting online from their website at carafem.org.
  • “carafem is proud to provide confidential, affordable, and reliable abortion care with 24/7 access in the city that never sleeps.
  • With telehealth abortion care, we’re able to break down more barriers to access.

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 2, 2024
Patient, Itch, Conference, EDT, Therapy

STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.

Key Points: 
  • STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.
  • A webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com .
  • An archived webcast recording will be available on the Cara website for approximately 30 days.

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 4, 2024
European Commission, Research, Investment, Research and development, Dialysis, Marketing, CSL, Sale, Conference, HCR, Safety, Civil service commission, Therapy, CSL Vifor, Administration, Patient, Clinical trial, ESRD, G&A, Clutch (eggs), Itch, Dermatology

STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • The Company enrolled 214 patients and expects topline efficacy and safety results from KOURAGE 1 Part A in the third quarter of 2024.
  • Final topline results from the first pivotal study are expected by the end of 2025 with the second pivotal study results in early 2026.
  • Wholesalers shipped 110,700 vials to dialysis centers during the fourth quarter of 2023 (an increase of 22% vs. the third quarter of 2023), the majority of which were vials reallocated within the Fresenius network of clinics.
  • Revenues: Total revenue was $3.0 million and $3.3 million for the three months ended December 31, 2023 and 2022, respectively.

Fairstone Achieves Silver Parity Certification From Women in Governance: A Significant Milestone in Gender Equality

Retrieved on: 
Wednesday, March 6, 2024
Silver, Certification, Parity, Committee, Poverty, Workplace, Partnership, Culture, Female, Diversity, Blog, Mentorship, Inclusion, Network, Canadian Women's Foundation, Environment, Workforce, International Women's Day, Nursing

Achieving Silver Parity Certifications is a testament to Fairstone's commitment to fostering diversity and inclusion.

Key Points: 
  • Achieving Silver Parity Certifications is a testament to Fairstone's commitment to fostering diversity and inclusion.
  • Since our pledge in 2021 to enhance gender representation across all levels of management, Fairstone has made substantial progress.
  • Today, Fairstone boasts parity at entry-level positions, with women constituting 63% of our workforce.
  • Additionally, we have reached complete parity within our executive management committee, delivering on our commitment to enhance gender diversity in leadership positions.

Cara Collective to Honor Allstate

Retrieved on: 
Tuesday, February 13, 2024
Rivers Casino, Trailblazer, Poverty, Foreign policy, Bank, River, Walking, Employment, Social impact, Workforce, Circuit court, Bank of America, JPMorgan Chase, Partnership, Nursing

CHICAGO, Feb. 13, 2024 /PRNewswire/ -- Cara Collective, an industry leader in workforce development, is pleased to announce it will honor Allstate at the upcoming 9th Annual Cara Gala on Friday, May 17, 2024. Allstate will receive the Trailblazer Award for its partnership with Cara Collective and for its commitment to closing the racial wealth gap.

Key Points: 
  • CHICAGO, Feb. 13, 2024 /PRNewswire/ -- Cara Collective , an industry leader in workforce development, is pleased to announce it will honor Allstate at the upcoming 9th Annual Cara Gala on Friday, May 17, 2024.
  • Allstate will receive the Trailblazer Award for its partnership with Cara Collective and for its commitment to closing the racial wealth gap.
  • "Through its influence and reputation, Allstate demonstrates its dedication to creating opportunity and improving communities by taking bold steps and challenging conventions," said Kathleen St. Louis Caliento, President & CEO of Cara Collective.
  • In addition to Allstate, Cara Collective will honor program graduate and staff member Da'Sean Hillsman with the Jesse Teverbaugh Distinguished Alumni Award.

Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026

Retrieved on: 
Monday, January 22, 2024
Patient, Therapy, Notalgia paresthetica, Disorder, CKD, PIN, FDA, EST, SVP, Pharmaceutical industry

– Cara ended 2023 with approximately $101 million in cash; runway extended into 2026 –

Key Points: 
  • – Cara ended 2023 with approximately $101 million in cash; runway extended into 2026 –
    – Company to host conference call and webcast today at 8:30 a.m. EST –
    STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses.
  • These measures will extend the Company’s cash runway into 2026, enabling the expected completion of the NP clinical program.
  • “Following careful consideration, we have decided to discontinue our work in advanced chronic kidney disease (CKD).
  • A data readout from the dose-finding portion of the program is expected in the third quarter of 2024.

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

Retrieved on: 
Monday, December 18, 2023
Atopic dermatitis, Notalgia paresthetica, Itch, BID, TCS, MD, Therapy, NRS, Week, KIND, Tablet, Patient, Safety, CKD, Pharmaceutical industry

STAMFORD, Conn., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KIND 1 study evaluating the efficacy and safety of oral difelikefalin as adjunct therapy to topical corticosteroids (TCS) for moderate-to-severe pruritus in adult patients with atopic dermatitis (AD). Oral difelikefalin as adjunct to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone, resulting in the Company’s decision to discontinue its clinical program in pruritus associated with atopic dermatitis.

Key Points: 
  • Oral difelikefalin as adjunct to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone, resulting in the Company’s decision to discontinue its clinical program in pruritus associated with atopic dermatitis.
  • “We are disappointed with the outcome of this study recognizing that comparing the adjunctive use of oral difelikefalin with TCS to TCS alone represented a high clinical bar based on anticipated real-world commercial use.
  • Oral difelikefalin as adjunct therapy to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone.
  • Oral difelikefalin was generally well tolerated with a safety profile similar to prior trials.

Cara Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Prospective payment system, Sale, CSL, ESRD, Safety, Therapy, Conference call, Investment, Clinical trial, Administration, Patient, Research, Dialysis, Notalgia paresthetica, CKD, Marketing, CSL Vifor, G&A, Atopic dermatitis, Conference, CMS, EST, KICK, Research and development, Kidney, Medicare, R, Itch, Pharmaceutical industry, Cryptocurrency, Music, Nursing, Life insurance

– Conference call today at 4:30 p.m. EST –

Key Points: 
  • – Conference call today at 4:30 p.m. EST –
    STAMFORD, Conn., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the third quarter ended September 30, 2023.
  • “We are pleased to have closed our non-dilutive financing transaction with HealthCare Royalty, which extends our cash runway into 2025,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics.
  • Wholesalers shipped 90,828 vials to dialysis centers during the third quarter of 2023.
  • Revenues: Total revenue was $4.9 million and $10.8 million for the three months ended September 30, 2023 and 2022, respectively.

Cara Conte Named One of Cablefax's Most Powerful Women of the Year

Retrieved on: 
Wednesday, December 6, 2023
DirecTV Stream, DIRECTV, EVP, Conte, FETV, Family, FMC, Woman, AT&T

SOUTH BEND, Ind., Dec. 6, 2023 /PRNewswire/ -- Family Entertainment Television, parent company of family-friendly networks FETV and FMC, announced today that Cara Conte, EVP Affiliate Sales, has been named one of Cablefax's Most Powerful Women of 2023.

Key Points: 
  • SOUTH BEND, Ind., Dec. 6, 2023 /PRNewswire/ -- Family Entertainment Television, parent company of family-friendly networks FETV and FMC, announced today that Cara Conte, EVP Affiliate Sales, has been named one of Cablefax's Most Powerful Women of 2023.
  • "I'm incredibly honored and humbled to receive this recognition from Cablefax alongside such an esteemed group of women leaders," said Conte.
  • "We are so proud of Cara for this tremendous accomplishment," said Adam Sumrall, Executive Vice President of FETV and FMC.
  • "Cara's commitment and diligence has played an integral role in the distribution growth of both FETV and FMC.